STAT+: Pharmalittle: House Dems slip drug pricing proposal into Covid-19 relief bill; FDA grants emergency use for Lilly drug
Top of the morning to you. Another busy day is unfolding here on the Pharmalot campus, where we are mulling over our cluttered calendar and plotting our next moves. No doubt, you can relate. After all, this is only the middle of the week and there is so much to be done. This calls, as you may imagine, for a hot cup of stimulation. We are reaching for salted caramel mocha — a touch of the Jersey Shore. Feel free to join us. Meanwhile, here are some tidbits. The world is a busy place, yes? Hope you make your way today …
The Food and Drug Administration authorized emergency use for an Eli Lilly (LLY) combination antibody therapy to fight Covid-19, Reuters says. Data from a late-stage clinical trial showed the two antibodies, bamlanivimab and etesevimab, helped cut the risk of hospitalization and death in Covid-19 patients by 70%. In collaboration with Amgen (AMGN), Lilly plans to manufacture up to 1 million doses of etesevimab for administration with bamlanivimab by mid-2021.
Continue to STAT+ to read the full story…
